OTCPK:NXOJ.F

Stock Analysis Report

Executive Summary

Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, the United States, and internationally.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Nexstim is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Nexstim's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

NXOJ.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

NXOJ.F

9.9%

US Medical Equipment

0.6%

US Market

No trading data on NXOJ.F.

No trading data on NXOJ.F.


Share holder returns

NXOJ.FIndustryMarket
7 Day0%1.1%-0.6%
30 Day0%0.6%2.2%
90 Dayn/a2.9%1.1%
1 Yearn/a10.8%9.9%2.9%0.6%
3 Yearn/a70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Nexstim's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Nexstim undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Nexstim is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Nexstim has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Nexstim's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Nexstim regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Nexstim expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-2.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Nexstim's revenue is expected to grow significantly at over 20% yearly.

Nexstim is not considered high growth as it is expected to be loss making for the next 1-3 years.

Nexstim's revenue growth is expected to exceed the United States of America market average.

Unable to compare Nexstim's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Nexstim's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Nexstim will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Nexstim performed over the past 5 years?

4.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Nexstim does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Nexstim's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Nexstim's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Nexstim has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Nexstim has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Nexstim improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Nexstim's financial position?


Financial Position Analysis

Nexstim is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Nexstim's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Nexstim has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Nexstim's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Nexstim has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Nexstim has sufficient cash runway for 1.1 years based on current free cash flow.

Nexstim has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -20.3% each year.


Next Steps

Dividend

What is Nexstim's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Nexstim's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Nexstim's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Nexstim has not reported any payouts.

Unable to verify if Nexstim's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Nexstim has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Nexstim's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Martin Jamieson (62yo)

3.3yrs

Tenure

0

Mr. Martin Jamieson serves as of Non-Executive Director of C-Major Ltd. Mr. Jamieson has been Chief Executive Officer at Nexstim Plc since April 21, 2016. Mr. Jamieson serves as Managing Director at Sims P ...


Management Age and Tenure

3.3yrs

Average Tenure

45yo

Average Age

The tenure for the Nexstim management team is about average.


Board Age and Tenure

2.3yrs

Average Tenure

55yo

Average Age

The average tenure for the Nexstim board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month individual insider trading information.


Ownership Breakdown


Management Team

  • Martin Jamieson (62yo)

    Chairman & CEO

    • Tenure: 3.3yrs
  • Henri Hannula (45yo)

    Vice President of International Sales & Marketing

    • Tenure: 0yrs
  • Mikko Karvinen (43yo)

    Chief Financial Officer

    • Tenure: 4.9yrs
  • Hanna Kotola

    Vice President of Legal

    • Tenure: 1.8yrs

Board Members

  • Ken Charhut (61yo)

    Director

    • Tenure: 6.5yrs
  • Alvaro Pascual-Leone

    Member of Scientific Advisory Board

    • Tenure: 0.3yrs
  • Juliet Thompson (53yo)

    Deputy Chairman of the Board

    • Tenure: 2.3yrs
  • Martin Jamieson (62yo)

    Chairman & CEO

    • Tenure: 3.3yrs
  • Rohan Hoare (55yo)

    Director

    • Tenure: 3.3yrs
  • Tomas Holmberg (54yo)

    Director

    • Tenure: 2.3yrs
  • Linda Carpenter

    Member of Scientific Advisory Board

    • Tenure: 0.3yrs
  • Turo Nurmikko

    Member of Scientific Advisory Board

    • Tenure: 0.3yrs

Company Information

Nexstim Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nexstim Plc
  • Ticker: NXOJ.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €5.523m
  • Listing Market Cap: €6.239m
  • Shares outstanding: 35.40m
  • Website: https://www.nexstim.com

Number of Employees


Location

  • Nexstim Plc
  • Elimäenkatu 9 B
  • Helsinki
  • Uusimaa
  • 510
  • Finland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NXTMSOM (OMX Nordic Exchange Stockholm)YesA SharesSESEKNov 2014
NXTMHHLSE (OMX Nordic Exchange Helsinki)YesA SharesFIEURNov 2014
5NXADB (Deutsche Boerse AG)YesA SharesDEEURNov 2014
NXOJ.FOTCPK (Pink Sheets LLC)SUB SHS BTAUSUSDApr 2019

Biography

Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, the United States, and internationally. The compa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/03 00:28
End of Day Share Price2019/04/11 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.